OncoMed Presents Updated Phase 1b Data For Tarextumab In Small Cell Lung Cancer

OncoMed Presents Updated Phase 1b Data For Tarextumab In Small Cell Lung Cancer

Redwood City, CA (GLOBE NEWSWIRE) – OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced updated survival data from a Phase 1b clinical trial …

(Visited 1 times, 1 visits today)
8
Like
Save

Comments

Comments are disabled for this post.